Pediatric Diffuse Midline Gliomas: An Unfinished Puzzle.

ABSTRACT: Diffuse midline glioma (DMG) is a heterogeneous group of aggressive pediatric brain tumors with a fatal prognosis. The biological hallmark in the major part of the cases is H3K27 alteration. Prognosis remains poor, with median survival ranging from 9 to 12 months from diagnosis. Clinical and radiological prognostic factors only partially change the progression-free survival but they do not improve the overall survival. Despite efforts, there is currently no curative therapy for DMG. Radiotherapy remains the standard treatment with only transitory benefits. No chemotherapeutic regimens were found to significantly improve the prognosis. In the new era of a deeper integration between histological and molecular findings, potential new approaches are currently under investigation. The entire in

SUBMITTER: Di Ruscio V 

PROVIDER: S-EPMC9497626 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature